Clinical significance of serum soluble T cell regulatory molecules in clear cell renal cell carcinoma

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Masuda, Akinori ^a   Arai, Kyoko ^a   Nishihara, Daisaku ^a   Mizuno, Tomoya ^a   Yuki, Hideo ^a   Kambara, Tsunehito ^a   Betsunoh, Hironori ^a   Abe, Hideyuki ^a   Yashi, Masahiro ^a   Fukabori, Yoshitatsu ^a   Yoshida, Ken Ichiro ^a   Kamai, Takao ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; SOLUBLE B7 H3; SOLUBLE INTERLEUKIN 2 RECEPTOR; SOLUBLE T CELL REGULATORY MOLECULE; TUMOR MARKER; UNCLASSIFIED DRUG; B7 ANTIGEN; CD276 PROTEIN, HUMAN; CTLA4 PROTEIN, HUMAN; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CAUSE SPECIFIC SURVIVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROTEIN BLOOD LEVEL; REGULATORY T LYMPHOCYTE; SURVIVAL RATE; SURVIVAL TIME; ADENOCARCINOMA; BLOOD; CASE CONTROL STUDY; CYTOLOGY; DISEASE COURSE; GENE EXPRESSION REGULATION; IMMUNE SYSTEM; LIVER TUMOR; MIDDLE AGED; PATHOLOGY; PROGNOSIS; YOUNG ADULT;

ADENOCARCINOMA, CLEAR CELL; ADULT; AGED; B7 ANTIGENS; CARCINOMA, RENAL CELL; CASE-CONTROL STUDIES; CTLA-4 ANTIGEN; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNE SYSTEM; INTERLEUKIN-2; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; RECEPTORS, INTERLEUKIN-2; T-LYMPHOCYTES, REGULATORY; YOUNG ADULT;

EID: 84904111445     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/396064     Document Type: Article

References (35)

1. + regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. Journal of Clinical Oncology 2006 24 7 1169 1177 10.1200/JCO.2005.03.6830 2-s2.0-33644988431 (Pubitemid 46638815)
2. Koreth J., Matsuoka K., Kim H. T., McDonough S. M., Bindra B., Alyea E. P. III, Armand P., Cutler C., Ho V. T., Treister N. S., Bienfang D. C., Prasad S., Tzachanis D., Joyce R. M., Avigan D. E., Antin J. H., Ritz J., Soiffer R. J., Interleukin-2 and regulatory T cells in graft-versus-host disease. New England Journal of Medicine 2011 365 22 2055 2066 10.1056/NEJMoa1108188 2-s2.0-82555168440
3. Saadoun D., Rosenzwajg M., Joly F., Six A., Carrat F., Thibault V., Sene D., Cacoub P., Klatzmann D., Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. The New England Journal of Medicine 2011 365 22 2067 2077 10.1056/NEJMoa1105143 2-s2.0-82555196118
4. Murphy W. J., Malek T. R., Ferrara L. M., A delicate balance: tweaking IL-2 immunotherapy. Nature Medicine 2012 18 2 208 209
5. Bluestone J. A., The Yin and Yang of interleukin-2-mediated immunotherapy. The New England Journal of Medicine 2011 365 22 2129 2131 10.1056/NEJMe1110900 2-s2.0-82555192217
6. Malek T. R., Castro I., Interleukin-2 receptor signaling: at the interface between tolerance and immunity. Immunity 2010 33 2 153 165 10.1016/j.immuni.2010.08.004 2-s2.0-77955890953
7. Sharon M., Klausner R. D., Cullen B. R., Chizzonite R., Leonard W. J., Novel interleukin-2 receptor subunit detected by cross-linking under high-affinity conditions. Science 1986 234 4778 859 863 10.1126/science.3095922 2-s2.0-0023010578 (Pubitemid 17186272)
8. Takeshita T., Asao H., Ohtani K., Ishii N., Kumaki S., Tanaka N., Munakata H., Nakamura M., Sugamura K., Cloning of the γ chain of the human IL-2 receptor. Science 1992 257 5068 379 382 10.1126/science.1631559 2-s2.0-0026684134
9. Gutgsell N. S., Malek T. R., Formation of high affinity IL-2 receptors is dependent on a nonligand binding region of the α subunit. Journal of Immunology 1994 153 9 3899 3907 2-s2.0-0028149322
10. Taniguchi T., Minami Y., The IL-2/IL-2 receptor system: a current overview. Cell 1993 73 1 5 8 10.1016/0092-8674(93)90152-G 2-s2.0-0027394657 (Pubitemid 23115443)
11. Waldmann T. A., The structure, function, and expression of interleukin-2 receptors on normal and malignant lymphocytes. Science 1986 232 4751 727 731 10.1126/science.3008337 2-s2.0-0022536230 (Pubitemid 16078718)
12. Schwartz R. H., A cell culture model for T lymphocyte clonal anergy. Science 1990 248 4961 1349 1356 10.1126/science.2113314 2-s2.0-0025339511
13. Greenwald R. J., Freeman G. J., Sharpe A. H., The B7 family revisited. Annual Review of Immunology 2005 23 515 548 10.1146/annurev.immunol.23.021704. 115611 2-s2.0-17644425689 (Pubitemid 40563179)
14. Prasad D. V. R., Nguyen T., Li Z., Yang Y., Duong J., Wang Y., Dong C., Murine B7-H3 is a negative regulator of T cells. Journal of Immunology 2004 173 4 2500 2506 10.4049/jimmunol.173.4.2500 2-s2.0-4043099691 (Pubitemid 39063108)
15. Brunet J. F., Denizot F., Luciani M. F., Roux-Dosseto M., Suzan M., Mattei M. G., Golstein P., A new member of the immunoglobulin superfamily-CTLA-4. Nature 1987 328 6127 267 270 10.1038/328267a0 2-s2.0-0023270567 (Pubitemid 17108278)
16. Krummel M. F., Allison J. P., CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. Journal of Experimental Medicine 1996 183 6 2533 2540 10.1084/jem.183.6.2533 2-s2.0-0029899783 (Pubitemid 26192363)
17. Sobin L. H., Wittekind C. H., TNM Classification of Malignant Tumours 2002 6th New York, NY, USA International Union Against Cancer, UICC, John Wiley & Sons
18. Kanda Y., Investigation of the freely available easy-to-use software "EZR" for medical statistics. Bone Marrow Transplantation 2013 48 3 452 458 10.1038/bmt.2012.244 2-s2.0-84875215709
19. Boyano M. D., Garcia-Vázquez M. D., López-Michelena T., Gardeazabal J., Bilbao J., Canavate M. L., Galdeano A. G. D., Izu R., Díaz-Ramón L., Raton J. A., Díaz-Pérez J. L., Soluble interleukin-2 receptor, intercellular adhesion molecule-1 and interleukin-10 serum levels in patients with melanoma. British Journal of Cancer 2000 83 7 847 852 10.1054/bjoc.2000.1402 2-s2.0-0033826940
20. Ottaiano A., Leonardi E., Simeone E., Ascierto P. A., Scala S., Calemma R., Bryce J., Caracò C., Satriano R. A., Gianfranco N., Franco R., Botti G., Castello G., Soluble interleukin-2 receptor in stage I-III melanoma. Cytokine 2006 33 3 150 155 10.1016/j.cyto.2006.01.002 2-s2.0-33644890456
21. Tartour E., Mosseri V., Jouffroy T., Deneux L., Jaulerry C., Brunin F., Fridman W. H., Rodriguez J., Serum soluble interleukin-2 receptor concentrations as an independent prognostic marker in head and neck cancer. The Lancet 2001 357 9264 1263 1264 10.1016/S0140-6736(00)04420-2 2-s2.0-0035925912 (Pubitemid 32539057)
22. Wu L., Chen K. Y., Chi K., Chen S., Liang M., Shiau C., Wang L., Liu Y., Chow K., Yen S., The significance of soluble interleukin-2 receptor in monitoring disease relapse in patients with nasopharyngeal cancer. Japanese Journal of Clinical Oncology 1998 28 12 729 732 10.1093/jjco/28.12.729 2-s2.0-0032245777 (Pubitemid 128525824)
23. Goto H., Tsurumi H., Takemura M., Ino-Shimomura Y., Kasahara S., Sawada M., Yamada T., Hara T., Fukuno K., Goto N., Okuno M., Takami T., Seishima M., Moriwaki H., Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma: in combination with the International Prognostic Index. Journal of Cancer Research and Clinical Oncology 2005 131 2 73 79 10.1007/s00432-004-0600-9 2-s2.0-19944432777 (Pubitemid 40192931)
24. Vonderheid E. C., Zhang Q., Lessin S. R., Polansky M., Abrams J. T., Bigler R. D., Wasik M. A., Use of serum soluble interleukin-2 receptor levels to monitor the progression of cutaneous T-cell lymphoma. Journal of the American Academy of Dermatology 1998 38 2 207 220 10.1016/S0190-9622(98)70597-3 2-s2.0-0031885856 (Pubitemid 28100835)
25. Kawashima O., Kamiyoshihara M., Sakata S., Endo K., Saito R., Morishita Y., The clinicopathological significance of preoperative serum-soluble interleukin-2 receptor concentrations in operable non-small-cell lung cancer patients. Annals of Surgical Oncology 2000 7 3 239 245 10.1007/BF02523660 2-s2.0-0033996905 (Pubitemid 30215164)
26. Matsumoto T., Furukawa A., Sumiyoshi Y., Akiyama K. Y., Kanayama H. O., Kagawa S., Serum levels of soluble interleukin-2 receptor in renal cell carcinoma. Urology 1998 51 1 145 149 10.1016/S0090-4295(97)00476-7 2-s2.0-0031891806 (Pubitemid 28092527)
27. Kim H., Kelly J., Leonard W. J., The basis for IL-2-induced IL-2 receptor α chain gene regulation: Importance of two widely separated IL-2 response elements. Immunity 2001 15 1 159 172 10.1016/S1074-7613(01)00167-4 2-s2.0-0034897188 (Pubitemid 32728329)
28. + regulatory T cells in immunological tolerance to self and non-self. Nature Immunology 2008 6 5 345 352 (Pubitemid 41716771)
29. Sakaguchi S., Yamaguchi T., Nomura T., Ono M., Regulatory T cells and immune tolerance. Cell 2008 133 5 775 787 10.1016/j.cell.2008.05.009 2-s2.0-43949105866 (Pubitemid 351707693)
30. Brivio F., Lissoni P., Fumagalli L., Rovelli F., Brivio R., Vigoré L., Messina G., Tisi E., Correlation between soluble IL-2 receptor serum levels and regulatory T lymphocytes in patients with solid tumors. International Journal of Biological Markers 2008 23 2 121 122 2-s2.0-52249119160
31. Yang J. C., Hughes M., Kammula U., Royal R., Sherry R. M., Topalian S. L., Suri K. B., Levy C., Allen T., Mavroukakis S., Lowy I., White D. E., Rosenberg S. A., Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. Journal of Immunotherapy 2007 30 8 825 830 10.1097/CJI.0b013e318156e47e 2-s2.0-37349072460 (Pubitemid 350295361)
32. Dong H., Strome S. E., Salomao D. R., Tamura H., Hirano F., Flies D. B., Roche P. C., Lu J., Zhu G., Tamada K., Lennon V. A., Celis E., Chen L., Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nature Medicine 2002 8 9 793 800 10.1038/nm0902-1039a 2-s2.0-18544363923
33. Brahmer J. R., Drake C. G., Wollner I., Powderly J. D., Picus J., Sharfman W. H., Stankevich E., Pons A., Salay T. M., McMiller T. L., Gilson M. M., Wang C., Selby M., Taube J. M., Anders R., Chen L., Korman A. J., Pardoll D. M., Lowy I., Topalian S. L., Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. Journal of Clinical Oncology 2010 28 19 3167 3175 10.1200/JCO.2009.26.7609 2-s2.0-77954899030
34. Frigola X., Inman B. A., Lohse C. M., Krco C. J., Cheville J. C., Thompson R. H., Leibovich B., Blute M. L., Dong H., Kwon E. D., Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma. Clinical Cancer Research 2011 17 7 1915 1923 10.1158/1078-0432.CCR-10-0250 2-s2.0-79953306651
35. Crispen P. L., Sheinin Y., Roth T. J., Lohse C. M., Kuntz S. M., Frigola X., Houston Thompson R., Boorjian S. A., Dong H., Leibovich B. C., Blute M. L., Kwon E. D., Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma. Clinical Cancer Research 2008 14 16 5150 5157 10.1158/1078-0432.CCR-08-0536 2-s2.0-52649160243